- Home
- FDMT vs PRQR Comparison
FDMT vs PRQR Comparison
Compare FDMT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- PRQR
- Stock Information
- Founded
- FDMT 2013
- PRQR 2012
- Country
- FDMT United States
- PRQR Netherlands
- Employees
- FDMT N/A
- PRQR N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- PRQR Health Care
- Exchange
- FDMT Nasdaq
- PRQR Nasdaq
- Market Cap
- FDMT 192.2M
- PRQR 179.1M
- IPO Year
- FDMT 2020
- PRQR 2014
- Fundamental
- Price
- FDMT $4.32
- PRQR $2.35
- Analyst Decision
- FDMT Buy
- PRQR Strong Buy
- Analyst Count
- FDMT 10
- PRQR 8
- Target Price
- FDMT $32.33
- PRQR $8.88
- AVG Volume (30 Days)
- FDMT 418.9K
- PRQR 365.1K
- Earning Date
- FDMT 08-07-2025
- PRQR 08-07-2025
- Dividend Yield
- FDMT N/A
- PRQR N/A
- EPS Growth
- FDMT N/A
- PRQR N/A
- EPS
- FDMT N/A
- PRQR N/A
- Revenue
- FDMT $23,000.00
- PRQR $21,212,711.00
- Revenue This Year
- FDMT $13,048.65
- PRQR N/A
- Revenue Next Year
- FDMT N/A
- PRQR N/A
- P/E Ratio
- FDMT N/A
- PRQR N/A
- Revenue Growth
- FDMT N/A
- PRQR 85.91
- 52 Week Low
- FDMT $2.24
- PRQR $1.07
- 52 Week High
- FDMT $28.93
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- FDMT 57.43
- PRQR 66.90
- Support Level
- FDMT $3.86
- PRQR $2.10
- Resistance Level
- FDMT $4.48
- PRQR $2.18
- Average True Range (ATR)
- FDMT 0.28
- PRQR 0.13
- MACD
- FDMT 0.01
- PRQR 0.01
- Stochastic Oscillator
- FDMT 89.81
- PRQR 56.92
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.